CA2631236C - Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy - Google Patents

Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy Download PDF

Info

Publication number
CA2631236C
CA2631236C CA2631236A CA2631236A CA2631236C CA 2631236 C CA2631236 C CA 2631236C CA 2631236 A CA2631236 A CA 2631236A CA 2631236 A CA2631236 A CA 2631236A CA 2631236 C CA2631236 C CA 2631236C
Authority
CA
Canada
Prior art keywords
expression
gene product
patient
level
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2631236A
Other languages
English (en)
French (fr)
Other versions
CA2631236A1 (en
Inventor
Steen Knudsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allarity Therapeutics Europe ApS
Original Assignee
Medical Prognosis Institute AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Prognosis Institute AS filed Critical Medical Prognosis Institute AS
Publication of CA2631236A1 publication Critical patent/CA2631236A1/en
Application granted granted Critical
Publication of CA2631236C publication Critical patent/CA2631236C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2631236A 2005-12-01 2006-12-01 Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy Active CA2631236C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200501696 2005-12-01
DKPA200501696 2005-12-01
PCT/IB2006/004048 WO2007072225A2 (en) 2005-12-01 2006-12-01 Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy

Publications (2)

Publication Number Publication Date
CA2631236A1 CA2631236A1 (en) 2007-06-28
CA2631236C true CA2631236C (en) 2019-10-29

Family

ID=38189039

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2631236A Active CA2631236C (en) 2005-12-01 2006-12-01 Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy

Country Status (5)

Country Link
EP (1) EP1960551A2 (ja)
JP (3) JP5984324B2 (ja)
CN (1) CN101365806B (ja)
CA (1) CA2631236C (ja)
WO (1) WO2007072225A2 (ja)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535518A (ja) * 2007-08-14 2010-11-25 エフ.ホフマン−ラ ロシュ アーゲー Egfr阻害剤治療のための予測マーカー
US9322065B2 (en) 2007-09-17 2016-04-26 Mdxhealth Sa Methods for determining methylation of the TWIST1 gene for bladder cancer detection
WO2010024374A1 (ja) * 2008-08-29 2010-03-04 学校法人北里研究所 Dnaメチル化阻害剤の薬剤効果検出方法
GB0816867D0 (en) * 2008-09-15 2008-10-22 Glaxosmithkline Biolog Sa Method
JP2012526828A (ja) * 2009-05-11 2012-11-01 バーグ バイオシステムズ,エルエルシー エピメタボリックシフター、多次元細胞内分子、または環境影響因子を使用する代謝性障害の治療方法
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
TW201136604A (en) * 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
US20120289583A1 (en) * 2009-12-31 2012-11-15 Curna, Inc. Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
WO2011085263A2 (en) 2010-01-11 2011-07-14 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
US9598734B2 (en) 2010-04-29 2017-03-21 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
RU2615684C2 (ru) 2010-06-14 2017-04-06 Ликера Биомед Са Специфическое антитело к s100a4 или его фрагмент (варианты), способ их получения (варианты), фармацевтическая композиция, их содержащая, гибридомная клеточная линия (варианты), конъюгат, композиция, способ предупреждения и/или лечения рака, метастазирования, ангиогенеза и воспалительных заболеваний, способ и набор для диагностики рака или заболевания, ассоциированного с воспалением, (варианты), способ детекции s100a4, способ создания индивидуальной терапии
WO2011160206A1 (en) 2010-06-23 2011-12-29 Morin Ryan D Biomarkers for non-hodgkin lymphomas and uses thereof
SG10201505769PA (en) 2010-07-27 2015-09-29 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP2614369B1 (en) 2010-09-10 2016-02-03 Epizyme, Inc. Method for determining the suitability of inhibitors of human ezh2 in treatment
CN102408478A (zh) * 2010-09-21 2012-04-11 复旦大学 一种人少突神经胶质瘤标志物map2蛋白及其用途
EP2658972A4 (en) * 2010-12-15 2015-05-06 Medimmune Llc MELANOMA TREATMENT
PL2666015T3 (pl) * 2011-01-21 2017-06-30 Basilea Pharmaceutica Ag Zastosowanie statminy jako biomarkera odpowiedzi lekowej na furazanobenzoimidazole
ES2762451T3 (es) 2011-04-04 2020-05-25 Berg Llc Tratamiento de tumores del sistema nervioso central con coenzima Q10
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
KR101439856B1 (ko) * 2011-06-02 2014-09-17 한국생명공학연구원 항-atic 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
WO2013078537A1 (en) * 2011-11-28 2013-06-06 National Research Council Of Canada Paclitaxel response markers for cancer
SG10201912312YA (en) 2012-01-31 2020-02-27 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer
US9663825B2 (en) * 2012-04-19 2017-05-30 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
RU2014148779A (ru) * 2012-05-04 2016-06-27 Новартис Аг Биомаркеры для терапии ингибитором iap
DK2872646T3 (en) * 2012-07-12 2017-12-04 Université Paris Descartes PROCEDURES FOR PREDICTING SURVIVAL TIME AND TREATMENT RESPONSE OF A PATIENT, SUFFERING A FAST CANCER WITH A SIGNATURE OF AT LEAST 7 GENES
MY180311A (en) 2012-10-15 2020-11-28 Epizyme Inc Substituted benzene compounds
EA032775B1 (ru) 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
ES2829415T3 (es) 2013-05-30 2021-05-31 Genomic Health Inc Algoritmo de perfil de expresión génica para calcular una puntuación de recurrencia para un paciente con cáncer de riñón
JP6595478B2 (ja) 2013-09-04 2019-10-23 バーグ エルエルシー コエンザイムq10の連続注入によるがんの治療方法
JP2017508469A (ja) * 2014-03-11 2017-03-30 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 癌悪性度、予後及び治療に対する反応性の決定
CN104945496B (zh) * 2014-03-31 2019-05-03 天津市应世博科技发展有限公司 一种多肽及其在制备与纯化对ehd2特异的抗体中的应用
CN103923212A (zh) * 2014-03-31 2014-07-16 天津市应世博科技发展有限公司 Ehd2抗体及其在制备乳腺癌免疫组化检测试剂中的应用
FR3025028A1 (fr) * 2014-08-22 2016-02-26 Acobiom Procede pour determiner le pronostic de survie d'un patient atteint d'un cancer du pancreas
DK3198035T3 (da) 2014-09-26 2023-01-30 Allarity Therapeutics Europe ApS Fremgangsmåder til forudsigelse af medicinrespons
KR101674874B1 (ko) * 2014-10-21 2016-11-22 한국원자력의학원 항암제 내성 예측용 바이오마커로서의 icam-3 및 이의 용도
CN105777901B (zh) * 2014-12-25 2019-07-09 中国科学院上海生命科学研究院 一种抗qki-5单克隆抗体及其制备与应用
WO2016121715A1 (ja) * 2015-01-26 2016-08-04 国立大学法人名古屋大学 肺がん患者の予後を評価するための情報を提供する方法、肺がん患者の予後予測方法、内部標準、抗体、肺がん患者の予後予測装置、予後予測装置のプログラム及び記録媒体
GB201503371D0 (en) * 2015-02-27 2015-04-15 Mission Therapeutics Ltd Methods of screening and treatment
CN104749381B (zh) * 2015-03-30 2017-03-15 石河子大学 组装抑制蛋白pfn2在制备食管癌诊断试剂中的用途
CN105132415A (zh) * 2015-08-19 2015-12-09 天津市康婷生物工程有限公司 锰超氧化物歧化酶sod2的体外分子检测方法及引物
CN105132429A (zh) * 2015-10-10 2015-12-09 华东理工大学 靶向人KPNB1基因的siRNA及其应用
CN105424935B (zh) * 2015-11-09 2017-08-25 吉林大学 多聚谷氨酰化dnajc7的新应用
CN105506107A (zh) * 2015-12-30 2016-04-20 杭州艾迪康医学检验中心有限公司 检测dock2基因多态热点突变情况的引物和方法
WO2017134231A1 (en) * 2016-02-05 2017-08-10 Bayer Pharma Aktiengesellschaft Compounds, compositions and methods for cancer patient stratification and cancer treatment
CN105787297A (zh) * 2016-03-12 2016-07-20 云南圣清环境监测科技有限公司 一种微生物修复系统活性评价的方法
WO2017167788A1 (en) * 2016-03-29 2017-10-05 Universite Paris Diderot Paris 7 Compositions comprising secreted extracellular vesicles of cells expressing nfatc4 useful for the treatment of cancer
CN110506127B (zh) * 2016-08-24 2024-01-12 维拉科特Sd公司 基因组标签预测前列腺癌患者对术后放射疗法应答性的用途
JP6779517B2 (ja) * 2016-09-02 2020-11-04 国立大学法人 鹿児島大学 抗癌剤の感受性及び癌の予後に対する診断マーカー
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
CN106399582B (zh) * 2016-12-20 2019-12-24 上海杏园瑞民生物工程有限公司 一种检测与结直肠癌靶向用药西妥昔单抗治疗敏感性相关基因的多态性的试剂盒及其应用
AU2017258901A1 (en) * 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
AU2018202878A1 (en) 2017-05-16 2018-12-06 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
CN107266567B (zh) * 2017-06-05 2021-06-04 高新 Lcrmp4单克隆抗体及其制备方法与应用
CN109207589A (zh) * 2017-07-05 2019-01-15 安徽普元生物科技股份有限公司 一步法实时荧光定量逆转录聚合酶链反应检测人细胞角蛋白7的试剂盒
US11452709B2 (en) * 2017-07-17 2022-09-27 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy
CN109387630A (zh) * 2017-08-14 2019-02-26 杭州源昶医药科技有限公司 用于预测吉西他滨药物敏感性的生物标记物及其用途
CN109470854B (zh) * 2017-09-08 2022-02-11 广州市丹蓝生物科技有限公司 肺癌诊断用蛋白芯片及试剂盒
WO2019144275A1 (zh) * 2018-01-23 2019-08-01 北京艾克伦医疗科技有限公司 鉴定肺癌状态的方法和试剂盒
US20220324835A1 (en) * 2018-01-26 2022-10-13 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof
CN108796077B (zh) * 2018-05-30 2021-11-09 朱运峰 在cfDNA中检测胞嘧啶脱氨酶及相关分子基因修饰差异的引物对组及试剂盒
EP3847282A4 (en) * 2018-09-06 2022-06-01 The Council of the Queensland Institute of Medical Research BIOMARKERS FOR CANCER THERAPY
CN113412259B (zh) 2018-10-15 2024-07-16 紐力克斯治疗公司 通过泛素蛋白酶体途径降解btk的双官能化合物
EP3874062A4 (en) * 2018-11-04 2022-08-24 PFS Genomics, Inc. METHODS AND GENOMIC CLASSIFIERS FOR PRODICTING BREAST CANCER AND PREDICTING THE BENEFITS OF ADJUVANT RADIATION THERAPY
CN109402260A (zh) * 2018-11-28 2019-03-01 陕西中医药大学 Rims3基因作为肝癌检测的生物标志物及应用
JP7232922B2 (ja) * 2019-01-17 2023-03-03 ジーニナス インコーポレイテッド 抗癌剤反応性予測用バイオマーカーおよびその用途
KR20210149757A (ko) 2019-04-09 2021-12-09 누릭스 테라퓨틱스 인코포레이티드 Cbl-b 억제용의 3-치환된 피페리딘 화합물, 및 암 백신 및/또는 종양용해 바이러스와 조합된 cbl-b 억제제의 용도
CN114206855A (zh) 2019-05-17 2022-03-18 紐力克斯治疗公司 用于Cbl-b抑制的氰基环丁基类化合物及其用途
US11401267B2 (en) 2019-06-26 2022-08-02 Nurix Therapeutics, Inc. Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
CN110331200A (zh) * 2019-06-28 2019-10-15 中山大学附属第六医院 Cd47检测试剂在制备结直肠癌对抗egfr单抗耐药诊断剂方面的应用
WO2021050490A1 (en) * 2019-09-13 2021-03-18 The Trustees Of Columbia University In The City Of New York Methods of enhancing radiotherapy using ferroptosis inducers as radiosensitizers
BR112022010349A2 (pt) 2019-12-04 2022-08-16 Nurix Therapeutics Inc Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
CN110951876A (zh) * 2019-12-17 2020-04-03 蔡清清 一种淋巴瘤预后试剂盒
CN111321228B (zh) * 2020-03-13 2021-03-05 中国医学科学院肿瘤医院 抗pd-1治疗敏感性相关基因及其应用
KR102363980B1 (ko) * 2020-04-13 2022-02-15 전남대학교산학협력단 전이성 뇌종양의 진단 또는 예후 분석용 바이오마커 및 이를 이용한 진단방법
AU2022254104A1 (en) 2021-04-08 2023-10-26 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds
TW202307203A (zh) * 2021-07-15 2023-02-16 日商富士軟片股份有限公司 特定細胞的品質管理方法及製造特定細胞之方法
CN113593700B (zh) * 2021-08-06 2024-02-27 江苏师范大学 分析肺癌进展的方法、装置、设备、介质及程序产品
CN113493840A (zh) * 2021-09-07 2021-10-12 北京泱深生物信息技术有限公司 子宫内膜癌诊断用标志物及其衍生产品和应用
GB202117299D0 (en) * 2021-11-30 2022-01-12 Queens Univ Of Belfast Method of prognosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072722A1 (en) * 2002-10-10 2004-04-15 Kornblith Paul L. Methods for assessing efficacy of chemotherapeutic agents
AU1814800A (en) * 1998-11-05 2000-05-22 Parker Hughes Institute (Ikaros) isoforms and mutants
CA2354084A1 (en) * 1998-12-08 2000-06-15 Sue Hilsenbeck Methods for detection of antiestrogen-resistant breast cancer
US6647341B1 (en) * 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
US7324926B2 (en) * 1999-04-09 2008-01-29 Whitehead Institute For Biomedical Research Methods for predicting chemosensitivity or chemoresistance
AU2003223367A1 (en) * 2002-03-28 2003-10-13 Medical College Of Ohio Method and compositions for the diagnosis and treatment of non-small cell lung cancer using gene expression profiles
JP2004043446A (ja) * 2002-05-15 2004-02-12 Schering Ag ヒストンデアセチラーゼ抑制剤及びその使用
DE60331537D1 (de) * 2002-05-17 2010-04-15 Celgene Corp Kombinationen zur behandlung von multiplem myelom
JP2007501608A (ja) * 2003-08-08 2007-02-01 株式会社 キャンバス 抗癌治療の効力を推定するための感受性試験
EP1682675A2 (en) * 2003-10-28 2006-07-26 Bayer HealthCare AG Methods and compositions for the response prediction of malignant neoplasia to treatment
US20050147978A1 (en) * 2003-12-30 2005-07-07 Jose Remacle Method for quantitative determination of multi-drug resistance in tumors
CN1922332B (zh) * 2003-12-31 2013-06-12 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
JP2007528730A (ja) * 2004-03-12 2007-10-18 ザ クイーンズ ユニヴァーシティ オブ ベルファスト 治療および測定法
AU2005229492A1 (en) * 2004-03-30 2005-10-13 Rigshospitalet Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors
ES2550614T3 (es) * 2004-04-09 2015-11-11 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia

Also Published As

Publication number Publication date
WO2007072225A3 (en) 2008-07-10
JP2016026496A (ja) 2016-02-18
WO2007072225A2 (en) 2007-06-28
CA2631236A1 (en) 2007-06-28
EP1960551A2 (en) 2008-08-27
WO2007072225A8 (en) 2008-11-06
CN101365806A (zh) 2009-02-11
JP5984324B2 (ja) 2016-09-06
JP2009523011A (ja) 2009-06-18
JP2014147386A (ja) 2014-08-21
CN101365806B (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
CA2631236C (en) Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8445198B2 (en) Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2008138578A2 (en) Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US20230381231A1 (en) Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
US10570457B2 (en) Methods for predicting drug responsiveness
EP2563936B1 (en) Methods and devices for predicting treatment efficacy
EP3458473B1 (en) Markers selectively deregulated in tumor-infiltrating regulatory t cells.
US20060073496A1 (en) Methods of identifying patients at risk of developing encephalitis following immunotherapy for Alzheimer's disease
US20080280779A1 (en) Gene expression profiling based identification of genomic signatures of multiple myeloma and uses thereof
CN103492590A (zh) 循环生物标志物
EP3404118A1 (en) Methods for predicting drug responsiveness in cancer patients
US10392667B2 (en) Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
EP3299478A1 (en) Methods for predicting drug responsiveness in cancer patients
US20210164056A1 (en) Use of metastases-specific signatures for treatment of cancer
US20210293820A1 (en) Methods of activating dysfunctional immune cells and treatment of cancer
US20230392215A1 (en) Biomarkers for cancer immunotherapy outcomes
EP2734233B1 (en) Methods of predicting host responsiveness to cancer immunotherapies by ex vivo induction of leukocyte-function-associated mrnas
CA3206126A1 (en) Biomarkers for breast cancer detection
WO2019178216A1 (en) Methods and compositions for treating, diagnosing, and prognosing ovarian cancer
US20100055686A1 (en) Methods for diagnosis of pediatric common acute lymphoblastic leukemia by determining the level of gene expression
Thomas et al. Gene expression profiling on pre‐and post‐erlotinib tumors from patients with head and neck squamous cell carcinoma
US20240318258A1 (en) Biomarkers for breast cancer detection
US20240254565A1 (en) Unique cancer associated fibroblast subsets predict response to immunotherapy
US11709164B2 (en) Approach for universal monitoring of minimal residual disease in acute myeloid leukemia
EP3464614B1 (en) Method for the prognosis of multiple myeloma

Legal Events

Date Code Title Description
EEER Examination request